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Abstract
Background: Prevention of rejection after renal transplantation requires treatment with immunosuppressive drugs. Data on
their in vivo effects on T- and B-cell phenotype and function are limited.
Methods: In a randomized double-blind placebo-controlled study to prevent renal allograft rejection, patients were treated
with tacrolimus, mycophenolate mofetil (MMF), steroids, and a single dose of rituximab or placebo during transplant
surgery. In a subset of patients, we analyzed the number and phenotype of peripheral T and B cells by multiparameter flow
cytometry before transplantation, and at 3, 6, 12, and 24 months after transplantation.
Results: In patients treated with tacrolimus/MMF/steroids the proportion of central memory CD4+ and CD8+ T cells was
higher at 3 months post-transplant compared to pre-transplant levels. In addition, the ratio between the percentage of
central memory CD4+ and CD4+ regulatory T cells was significantly higher up to 24 months post-transplant compared to
pre-transplant levels. Interestingly, treatment with tacrolimus/MMF/steroids resulted in a shift toward a more memory-like
B-cell phenotype post-transplant. Addition of a single dose of rituximab resulted in a long-lasting B-cell depletion. At 12
months post-transplant, the small fraction of repopulated B cells consisted of a high percentage of transitional B cells.
Rituximab treatment had no effect on the T-cell phenotype and function post-transplant.
Conclusions: Renal transplant recipients treated with tacrolimus/MMF/steroids show an altered memory T and B-cell
compartment post-transplant. Additional B-cell depletion by rituximab leads to a relative increase of transitional and
memory-like B cells, without affecting T-cell phenotype and function.
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Introduction
Life-long use of immunosuppressive drugs is required to prevent
rejection after renal transplantation. Nevertheless, the continuous
use of immunosuppressive drugs does not preclude the develop-
ment of chronic rejection, which is a major cause of long-term
allograft loss [1]. T cells play an important role in the pathogenesis
of rejection via the recognition of alloantigens, resulting in T-cell
activation, proliferation, and differentiation into CD8+ cytotoxic T
cells and CD4+ T helper cells [2]. Therefore, the most commonly
used immunosuppressive drugs in transplantation are directed
against T cells to inhibit these processes [3]. On the other hand,
regulatory T cells are able to suppress the immune response and
prevent allograft rejection [4]. The balance between memory and
regulatory T cells during the course after transplantation can be
used to predict renal graft rejection following the reduction of
immunosuppressive therapy [5]. Next to T cells, B cells can be
involved in graft rejection [6]. The presence of B-cell clusters in
renal grafts during acute rejection or the presence of anti-HLA
antibodies before transplantation is associated with poorer graft
survival [7–9]. Notably, B cells can induce alloimmune responses
by acting as professional antigen presenting cells, or by the
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production of various (pro-)inflammatory cytokines [10]. There-
fore, depletion of B cells in renal transplant recipients might help
to prevent allograft rejection. Current immunosuppressive regi-
mens consisting of steroids, a calcineurin-inhibitor, and mycophe-
nolate mofetil (MMF) inhibit B-cell function directly due to
inhibition of their proliferation and indirectly via the inhibition of
T-cell help. B cells can also be selectively depleted by rituximab
(RTX), an anti-CD20 monoclonal antibody. RTX is successfully
used in the treatment of B-cell malignancies and autoimmune
disorders mediated by T and B cells [11,12]. Although the major
target of RTX-based treatment was to reduce the levels of
circulating autoantibodies, additional B-cell functions may be
affected, such as antigen presentation and cytokine production
[13]. Furthermore induction of regulatory T cells (TREGS) was
reported after RTX treatment in patients with lupus nephritis
[14]. Therefore, next to its effect on B cells, RTX might decrease
the chance of rejection after transplantation by affecting the T-cell
compartment. Remarkably little is known about the effects of the
currently used immunosuppressive strategies on the phenotype
and function of T and B cells during the course after renal
transplantation. Advancements in multiparameter flow cytometry
have made it possible to analyze the effects of immunosuppressive
agents on various T- and B-cell subsets in more detail. We had the
opportunity to study the effects of standard immunosuppression
(tacrolimus, MMF and steroids), with or without the addition of
RTX induction therapy on the phenotype and function of T and B
cells over time in renal transplant recipients participating in a
randomized placebo-controlled trial, studying the efficacy and
safety of RTX added to standard immunosuppression. To avoid
bias by other immunological events as much as possible, we
analyzed only Cytomegalovirus (CMV) seronegative patients who
received a kidney from a CMV seronegative donor, did not
experience a rejection episode, and were not treated with
additional immunosuppressive drugs during the follow-up period.
Materials and Methods
Patients
Patients were selected from participants of a clinical trial with
RTX in renal transplantation at our hospital (ClinicalTrials.gov,
NCT00565331). This study investigated the effectiveness and
safety of RTX for prophylaxis of acute rejection after renal
transplantation. Patients were randomized between treatment with
a single dose of RTX (375 mg/m2) or placebo during transplant
surgery. Concomitant immunosuppression consisted of tacrolimus,
MMF, and steroids. Patients received 100 mg of prednisolone
intravenously during the first 3 days after transplantation and
subsequently an oral dose of 15–25 mg/day, tapered to a
maintenance dose of 0.1 mg/kg/day. Tacrolimus was started at
0.2 mg/kg/day and the dose was subsequently adjusted to achieve
whole-blood trough levels of 15–20 ng/ml during the first 2 weeks,
10–15 ng/ml during weeks 3–6, and 5–10 ng/ml from week 7.
MMF was administered at 1000 mg twice daily with a dose
reduction to 750 mg twice daily at 2 weeks after transplantation,
and discontinued after 6 months.
The current study was carried out as preplanned side study of
the clinical trial. To create a homogeneous study population
without disturbing immunological events, we selected patients who
did not meet the primary end point of the clinical trial (biopsy-
proven acute rejection). Moreover, we investigated only Cyto-
megalovirus (CMV) seronegative patients who received a kidney
from a CMV seronegative donor (and thus did not develop CMV
infection), and we excluded patients in whom the immunosup-
pressive treatment was changed during the follow-up period. After
applying these selection criteria, all remaining patients were
included: 14 patients in the group treated with tacrolimus, MMF
and steroids, and 12 patients in the group additionally treated with
RTX (Figure S1). Peripheral blood mononuclear cells (PBMCs) of
4 standard-treated patients and 3 RTX-treated patients were not
available at 24 months after transplantation. Table 1 summarizes
the characteristics of all patients. The study was approved by the
Institutional review board of the Radboudumc Nijmegen. Written
informed consent was obtained from all participants.
Cells
Peripheral blood samples were obtained before transplantation,
and up to 24 months after transplantation. Whole blood counts
were performed and PBMCs were isolated by density gradient
centrifugation using Lymphoprep (Lucron, Dieren, The Nether-
lands). PBMCs were cryopreserved in liquid nitrogen until
analysis. For each patient longitudinal flow cytometric analysis
was performed for all available samples at the same time.
Flow cytometry
For cell surface staining, the following fluorochrome-conjugated
monoclonal antibodies were used CD3(UCHT1), CD4(13B8.2),
CD8(B9.11), CD19(J3-119), CD24(ALB9), CD38(LS198-4-3),
CD45(J.33), CD45RO(UCHL1), CD127(R34.34) and
IgD(IADB6) (all from Beckman-Coulter, Mijdrecht, The Nether-
lands), CD25(M-A251), CCR4(1G1), CCR6(11A9) and
CXCR3(1C6/CXR3) (BD Biosciences, Erembodegem, Belgium),
and BAFF-R(11C1) (BioLegend, Uithoorn, The Netherlands).
Intracellular analysis of IL-2(MQ1-17H12) (BD Biosciences), IL-
4(8D4–8), IL-17(EBIO64CAP17), IFNc(4S.B3) (eBioscience, San
Diego, CA, USA), and TNFa(Mab11) (Dako, Glostrup, Denmark)
was performed after fixation and permeabilization, using Fix and
Perm reagent (eBioscience). Before intracellular cytokine mea-
surement, the cells were stimulated for 4 hours with PMA
(12.5 ng/ml), ionomycin (500 ng/ml) and Brefeldin A (5 mg/ml;
Sigma-Aldrich, Zwijndrecht, The Netherlands).
The cell phenotype was analyzed by five-color (FC500) or ten-
color flow cytometry (Navios), and data were analyzed using
Kaluza software (all from Beckman-Coulter). Isotype controls or
unstained cells were used for gate settings. Cell populations.0.1%
of the CD45+ lymphocyte population with a threshold of more
than 50 cells were considered reliable.
Statistical analysis
Continuous data are expressed as box plots displaying the
median, 25th and 75th percentiles as the box, and the 5th and
95th percentiles as whiskers. Wilcoxon signed rank test was used to
test differences between each follow-up and pre-transplantation
value within the triple immunosuppression-treated group. Statis-
tical testing between RTX- and placebo-treated patients was
performed according to distribution and type of data (unpaired T
test, Mann-Whitney U, or Fisher’s exact tests). P,0.05 was
considered statistically significant. Statistical analysis was per-
formed using GraphPad Prism 5.03 (GraphPad Software Inc., La
Jolla, CA, USA).
Results
Phenotype and function of T cells in renal transplant
recipients after treatment with tacrolimus, MMF and
steroids
CD4+ and CD8+ T cells can be divided into naive, central and
effector memory, and highly differentiated memory cells based on
Peripheral T and B Cells in Renal Transplant Recipients
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CD27 and CD45RO expression. [15]. The absolute numbers of
CD4+ and CD8+ T cells in peripheral blood did not change during
the use of triple drug immunosuppression after transplantation
(Figure 1A–C). However, the percentages of central memory
(TCM; CD27
+CD45RO+) CD4+ and CD8+ T cells were signifi-
cantly higher at 3 months after transplantation compared to before
transplantation, while the percentages of effector memory (TEM;
CD272CD45RO+) CD4+ and CD8+ T cells, and regulatory
(TREGS; CD25
hiFOXP3+) CD4+ T cells were significantly
decreased. The percentages of naive (TN; CD27
+CD45RO2)
and highly differentiated memory (TEMRA; CD27
2CD45RO2)
CD4+ and CD8+ T cells were comparable to pre-transplant levels.
Next to the T-cell subset distribution, the ratio between memory
and regulatory T cells might be an important determinant of the
risk of rejection [16]. Interestingly, the CD4+ TCM/CD4
+ TREGS
ratio significantly increased from 3 months after transplantation
and remained elevated compared to the pre-transplant ratio
(Figure 1D). The CD4+ TEM/CD4
+ TREGS ratio after transplan-
tation was comparable to pre-transplant levels. Finally, we
determined the expression of chemokine receptors associated with
T helper (Th) 1 (CXCR3), Th2 (CCR4), and Th17 (CCR6) cells
(Figure 1E). The percentage of CXCR3+ and CCR6+ CD4+ T
cells increased during immunosuppressive treatment, whereas
triple drug immunosuppression did not affect the percentage of
CCR4+ CD4+ T cells.
Although triple drug immunosuppression had minimal effects
on the phenotype of peripheral T cells, this did not preclude an
effect on functional capacities. To assess the cytokine producing
capacity of circulating T cells, PBMCs were ex vivo stimulated for
4 hours with PMA, ionomycin and Brefeldin A. Effector cytokine
production was assessed using intracellular cytokine staining in
both CD4+ and CD8+ T cells. The percentage of IL-2, IL-4, IL-
17, and TNFa producing CD4+ cells decreased at 3 months after
transplantation compared to pre-transplant levels. Hereafter, the
production of all cytokines but TNFa returned to baseline levels
within 24 months after transplantation (Figure 2). Ex vivo IFNc
production was not affected by triple drug immunosuppression,
nor was cytokine producing capacity of CD8+ T cells. Taken
together, within the T-cell compartment, the most notable changes
were found in the effector CD4+ T-cell pool.
Under treatment with tacrolimus, MMF and steroids,
renal transplant recipients develop a memory-like B-cell
phenotype
During immunosuppressive treatment, the absolute B-cell
numbers in peripheral blood were comparable to pre-transplant
levels up to 24 months after transplantation (Figure 3A). To define
whether the composition of the peripheral B-cell compartment was
affected, we characterized CD19+ B cells using the Bm1-Bm5
classification [17]. Compared to pre-transplant levels, the
percentages of naive Bm2 (IgD+CD38+) and transitional Bm2’
(IgD+CD38++) CD19+ cells were lower, and the percentage of late
memory Bm5 (IgD2CD382) cells was higher after transplantation
(Figure 3B–C). This shift to a more memory-like phenotype was
accompanied by an increase in the percentage of virgin naive Bm1
cells, probably needed for B-cell renewal. Accordingly, using an
alternative terminology for B cells, the percentages of transitional
CD24++CD38++, mature CD24+CD38+, and naive IgD+CD272 B
cells were decreased, while there was a relative increase in
CD24++CD382 memory and IgD2CD27+ switched memory B
cells (Figure S2). At 12 and 24 months after transplantation, there
was a higher percentage of CD80+ and CD95+ B cells as
compared to before transplantation, supporting the more complete
differentiation towards memory cells within the B-cell compart-
ment (Figure 3D). The majority of B cells remained positive for B-
cell activating factor receptor (BAFF-R) after transplantation.
Interestingly, the expression level of BAFF-R increased after
transplantation, as documented by an increase in median
fluorescence intensity (MFI; Figure 3E–F). Overall, renal trans-
plant recipients treated with tacrolimus, MMF and steroids
developed a more memory-like B-cell phenotype.
A single dose of RTX results in a long lasting B-cell
depletion in peripheral blood without affecting the T-cell
compartment
The participation of renal transplant recipients in a randomized
double-blind placebo-controlled study evaluating the efficacy and
safety of RTX when added to triple drug immunosuppression gave
us the opportunity to study the effects of additional B-cell depletion
on the phenotype and function of T and B cells. RTX treatment
resulted in a nearly complete depletion of B cells from the
peripheral lymphocyte population up to 12 months after
transplantation. Remarkably, the B-cell depletion after a single
dose of RTX was long lasting. The absolute numbers of B cells
Table 1. Patient characteristics.
Triple IS Triple IS + rituximab P
N 14 12
Median age at Tx, years (range) 50 (20–73) 57 (25–66) 0.440
Sex, no. male (%) 11 (79%) 7 (58%) 0.401
Type of dialysis 0.446
- Hemodialysis 6 5
- Peritoneal dialysis 2 4
- None 6 3
Median PRA, % (range) 0 (0–58) 0 (0–10) 0.852
Living donor, no. (%) 13 (93%) 8 (67%) 0.217
HLA mismatches total, median (range) 4 (2–6) 3 (1–5) 0.224
IS: immunosuppression.
doi:10.1371/journal.pone.0112658.t001
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remained quite low at 24 months after RTX treatment with a
median of 9.7 B cells/ml (range 3.0–294.8) compared to a median
of 116.4 B cells/ml (range 49.7–379.7) in patients not treated with
RTX (Figure 4A–B). Interestingly, at 12 months the percentage of
Bm2’ (IgD++CD38++) and Bm3+4 (IgD2CD38++) cells was
significantly higher in RTX-treated patients, while the percentages
of Bm1 (IgD+CD382) and Bm2 (IgD+CD38+) cells were lower in
RTX-treated patients. (Figure 4C). Accordingly, the percentages
of CD24++CD38++ transitional and IgD2CD27+ switched mem-
ory B cells were higher in RTX-treated patients, while the
percentages of IgD+CD272 naı¨ve B cells were lower in RTX-
treated patients (Figure S3A). Fitting with the relative increase of
Bm3+4 (IgD2CD38++) cells, there was an increase in the
percentage of CD80+ and CD95+ B cells at 12 and/or 24 months
after transplantation (Figure 4D). Remarkably, the percentage of
BAFF-R+ B cells was lower in RTX-treated patients at 3 and 12
months after transplantation. In addition, the BAFF-R expression
(MFI) on B cells of RTX-treated patients was lower up to 24
months after transplantation (Figure 4D).
Next, we analyzed whether the long-lasting B-cell depletion with
a relative increase of transitional B cells resulted in changes in the
T-cell compartment. There was no significant effect of RTX
treatment on the absolute numbers and percentages of CD4+ and
CD8+ T cells or on the subset distribution and phenotype of these
cells (Figure S3B). In addition, in vivo B-cell depletion with RTX
had no effect on the production of IL-2, IL-4, IL-17, IFNc and
TNFa by ex vivo stimulated T cells (Figure S3C).
Discussion
Despite the extensive clinical experience with currently used
immunosuppressive drug regimens, there are limited data
Figure 1. Subset distribution of circulating T cells in renal transplant recipients after treatment with tacrolimus, MMF and steroids
over time. (A) Representative dot plots for a renal transplant recipient showing CD3+CD4+ and CD3+CD8+ T cells within the CD45+ lymphocyte
population. Circulating CD4+ and CD8+ T cells can be characterized as naive (TN; CD27
+CD45RO2), central memory (TCM; CD27
+CD45RO+), effector
memory (TEM; CD27
2CD45RO+) and highly differentiated memory (TEMRA; CD27
+CD45RO2) cells. Furthermore, CD4+ T cells can be characterized as
regulatory T cells (TREGS; CD25
hiFOXP3+). (B) Shown are the absolute numbers of CD4+ T cells and the percentages of TN, TCM and TEM within the CD4
+
T-cell population for 14 triple immunosuppression-treated patients before transplantation (t = 0) and at 3, 6, 12 and 24 months after transplantation
(n = 10 at 24 m). (C) As described under B, for CD8+ T cells. (D) The ratio between the percentage of CD4+ TCM or TEM and the percentage of TREGS. (E)
Longitudinal analysis of the percentages of CXCR3+, CCR4+, and CCR6+ cells within the CD4+ T-cell population of 14 triple immunosuppression-
treated patients (n = 10 at 24 m). Results are shown as box plots displaying the median, 25th and 75th percentiles as the box, and the 5th and 95th
percentiles as whiskers. Significant differences are indicated compared to pre-transplant levels: *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0112658.g001
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available regarding their effects on the peripheral lymphocyte
compartment after kidney transplantation. One study describes
the effects of cyclosporine, MMF, steroids, and anti-CD25
monoclonal antibody therapy on T and B cells of mainly CMV
seropositive renal transplant recipients at 6, 24, and 60 months
after transplantation [18]. This therapy resulted in an increased
Figure 2. Ex vivo cytokine production by circulating T cells in renal transplant recipients after treatment with tacrolimus, MMF and
steroids. Peripheral blood mononuclear cells (PBMCs) were stimulated for 4 hours in the presence of PMA, ionomycin and Brefeldin A. Shown are the
percentages IL-2, IL-4, IL-17, IFNc or TNFa-producing cells within the CD4+ or CD8+ T-cell population of 14 triple immunosuppression-treated patients
before transplantation (t = 0) and at 3, 6, 12, and 24 months after transplantation (n = 10 at 24 m). Results are shown as box plots displaying the
median, 25th and 75th percentiles as the box, and the 5th and 95th percentiles as whiskers. Significant differences are indicated compared to pre-
transplant levels: *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0112658.g002
Figure 3. Longitudinal analysis of circulating B cells in renal transplant recipients after treatment with tacrolimus, MMF and
steroids. (A) Shown are the absolute numbers of CD19+ B cells of 14 triple immunosuppression-treated patients before transplantation (t = 0) and at
3, 6, 12, and 24 months after transplantation (n = 10 at 24 m). (B) Representative dot plots for a renal transplant recipient over time using the Bm1-
Bm5 classification: Bm1 (IgD+CD382), Bm2 (IgD+CD38+), Bm2’ (IgD+CD38++), Bm3+4 (IgD2CD38++), Early Bm5 (IgD2CD38+) and Late Bm5
(IgD2CD382) cells within the CD19+ B-cell population. (C) Shown are the percentages of the different B-cell subsets using the Bm1-Bm5 classification
over time. (D) Shown are the percentages of CD80+, CD95+, and BAFF-receptor+ (BAFF-R) cells within the CD19+ B-cell population. (E) Overlay plot of
the BAFF-R expression (MFI: median fluorescence intensity) within the CD19+ B-cell population of one patient before transplantation (pre-Tx) and 24
months (24 m) after transplantation under treatment with tacrolimus, MMF and steroids. Gray line shows unstained cells. (F) Summary graph showing
the BAFF-R MFI of 14 triple immunosuppression-treated patients before over time (n = 10 at 24 m). Results are shown as box plots displaying the
median, 25th and 75th percentiles as the box, and the 5th and 95th percentiles as whiskers. Significant differences are indicated compared to pre-
transplant (pre-Tx; t = 0) levels: *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0112658.g003
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percentage of CD4+CD25+ TREGS and CD27
+ memory B cells in
renal transplant recipients compared to healthy donors [18], but
the data were not compared with pre-transplant levels. In contrast,
we performed a longitudinal analysis of T- and B-cell phenotype
and function in CMV seronegative patients who received a kidney
from a CMV seronegative donor and did not experience a
rejection episode up to 24 months after transplantation. In this
homogeneous patient population, not affected by major immuno-
logical events, we showed that treatment with the combination of
tacrolimus, MMF and steroids had no effects on the total number
of T and B cells. Nevertheless, these patients had a higher
proportion of central memory CD4+ and CD8+ T cells at 3
months after transplantation compared to pre-transplant levels.
Interestingly, the triple drug immunosuppression resulted in a shift
toward a more memory-like phenotype in the B-cell population.
Addition of a single dose of RTX resulted not only in a long-
lasting B-cell depletion, but also in a higher percentage of
transitional B cells upon B-cell recovery at 12 months post-
transplant. The additional RTX treatment had no effect on the T-
cell phenotype.
Although tacrolimus, MMF, and steroids mainly target T-cell
activation, proliferation, and differentiation [3,19], we found that
treatment with a combination of tacrolimus, MMF, and steroids,
induced only marginal changes in the peripheral T-cell phenotype.
These changes were mainly present within the first 6 months after
transplantation, which suggests a role for MMF, as this drug was
discontinued at 6 months after transplantation. Ex vivo, the T cells
collected from patients treated with triple immunosuppressive
Figure 4. Longitudinal analysis of circulating B cells in renal transplant recipients after treatment with tacrolimus, MMF and
steroids, and a single dose of rituximab (RTX) during transplant surgery. (A) Representative dot plots of CD19+ B cells within the CD45+
lymphocyte population for a RTX-treated and a triple immunosuppression (IS)-treated patient before transplantation (pre-Tx) and at 3, 12, and 24
months after transplantation. (B) Shown are the absolute numbers of CD19+ B cells for RTX-(gray, n = 12) and triple IS-treated (white, n = 14) patients
before transplantation (t = 0) and up to 24 months after transplantation (n = 10 and n= 9 at t = 24 m, respectively). (C) Pie charts depicting the
distribution the different B cells subsets over time using the Bm1-Bm5 classification as depicted in Figure 3B: Bm1 (IgD+CD382), Bm2 (IgD+CD38+),
Bm2’ (IgD+CD38++), Bm3+4 (IgD2CD38++), Early Bm5 (IgD2CD38+) and Late Bm5 (IgD2CD382) cells within the CD19+ B-cell population. Data are
represented as means of 14 triple IS+RTX-treated and 12 IS-treated patients before transplantation (pre-Tx) and at 3, 12, and 24 months after
transplantation (n = 10 and n= 9 at t = 24 m, respectively). (D) Shown are the percentages of CD80+, CD95+ and BAFF-R+ cells within the CD19+ B-cell
population for RTX- (gray, n = 12) and triple IS-treated (white, n = 14) patients before transplantation (t = 0) and up to 24 months after transplantation.
Results are shown as box plots displaying the median, 25th and 75th percentiles as the box, and the 5th and 95th percentiles as whiskers. Significant
differences are indicated by asterisks: **P,0.01.
doi:10.1371/journal.pone.0112658.g004
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therapy were functional, suggesting that they are only suppressed
when the drug is present (during treatment). In addition, we found
that the ratio between CD4+ central memory and TREGS was
increased under triple drug immunosuppressive therapy. Con-
comitantly, we observed a relative increase of CXCR3+ and
CCR6+ CD4+ T cells, chemokine receptors associated with
memory or activated Th1 and Th17 cells, respectively. This
expression enables them to migrate toward inflammatory sites that
express their cognate chemokines [20], such as observed in the
graft during rejection [21] and on activated human primary
tubular epithelial cells [22].
With respect to B cells, mycophenolic acid, but not tacrolimus,
has been shown to inhibit the proliferation and immunoglobulin
production in vitro [23]. However, in patients with systemic lupus
erythematosus who were treated with MMF, the number and
phenotype of B cells were similar to that in controls without
immunosuppressive therapy [24]. In our cohort, discontinuation of
MMF at 6 months after transplantation resulted in a relative
increase of virgin naive Bm1 cells, while naive Bm2 cells were
decreased compared to pre-transplant levels. Transitional Bm2
cells remained low up to 24 months after transplantation,
suggesting that their development is mainly suppressed by
treatment with tacrolimus and/or steroids. Finally, following the
discontinuation of MMF, the percentage of memory B cells
became comparable to levels before transplantation. Steroids were
also found to have clear effects on B cells; ex vivo immunoglobulin
production by PBMC was decreased during treatment with a high
dose of prednisolone (60 mg) while a lower dose (30 mg) resulted
in an increased production after stimulation [25]. Others have
described that steroids have an effect on B-cell activation, while
proliferation and activation are less affected [26]. Under combined
treatment with tacrolimus, MMF, and steroids, our renal
transplant recipients had a more memory-like B-cell phenotype
compared to before transplantation. This relative increase of
memory B cells was also found in a patient cohort treated with
cyclosporine, MMF, steroids, and an anti-CD25 monoclonal
antibody [18]. The observed memory-like B-cell phenotype was
accompanied by an increased percentage of CD80+ and CD95+ B
cells, which may be explained by the preferential expression of
these molecules on memory-like B cells [17].
Treatment with RTX provides a highly efficient means for the
(temporary) depletion of B cells, with potential suppression of B
cell-associated anti-graft responses. Adding a single dose of RTX
to the combination of tacrolimus, MMF, and steroids in our
patients indeed resulted in a long lasting B-cell depletion in
peripheral blood. A remarkable characteristic of the returning B
cells was a decreased expression of the receptor for B-cell
activating factor (BAFF), an essential growth factor for B cells
[27]. The decreased percentage of BAFF-R+ B cells after RTX
treatment, which was also found in patients with rheumatoid
arthritis [28] may be due to a relative increase of memory-like B
cells, which have lower or no BAFF-R expression [27]. In
addition, treatment with B-cell depleting agents has previously
been shown to elevate BAFF levels [29–31], and increased BAFF
levels in turn were inversely correlated with BAFF-R expression
during B-cell repopulation [30,32]. Another interesting observa-
tion was an increase in the percentage of transitional B cells at 12
months after treatment with RTX compared to triple immuno-
suppression therapy alone. Interestingly, BAFF-R deficiency in
patients with common variable immunodeficiency (CVID) was
associated with B-cell lymphopenia and a relative increase in the
number of transitional B cells [33]. Taken together, an increase in
BAFF level, reduced BAFF-R expression, and an increase in the
proportion of transitional B cells appear to be interrelated
phenomena which are associated with RTX treatment.
Upon activation, B cells are able to proliferate, produce various
cytokines and process antigen for presentation to T cells [34–36].
Previously, we showed that in vitro RTX treatment can affect B-
cell phenotype and function, resulting in an altered outcome of B-
T-cell interaction upon stimulation [37]. However, in contrast, we
did not observe any changes in the T-cell compartment in our
patients treated with RTX. In another ex vivo study, we neither
were able to show that RTX influenced the production of IL-17
and other monocyte- and T-cell-derived cytokines by PBMCs
[38]. It should be noted however that we only analyzed peripheral
blood T cells. From a previous study in renal transplant patients,
we know that a single dose of RTX leads a to nearly complete B-
cell depletion in peripheral blood, but not in secondary lymphoid
organs, and that these remaining B cells have different functional
capacities [39]. From our current data, it seems that this
population of mostly memory type B cells residing in lymphoid
organs does not noticeably affect the peripheral blood T-cell
compartment as compared to transplant recipients on triple
immunosuppression without RTX. Interestingly, several studies on
patients with autoimmune disease revealed that the T-cell
compartment was affected upon RTX treatment [12,40,41].
However, in most of these patients the cumulative dose of RTX
was higher than in our patients, who received only a single,
relatively low dose [40].
In summary, we have demonstrated that treatment of renal
transplant recipients with tacrolimus, MMF and steroids leads to
alterations in the T- and B-cell compartments. This detailed
longitudinal analysis provides more insight into the immune status
of renal transplant recipients with stable graft function and may be
used as a reference in the monitoring of renal transplant patients.
Supporting Information
Figure S1 Patient selection for the side study of the
clinical trial. CMV, Cytomegalovirus; D, donor; R,
recipient.
(EPS)
Figure S2 Longitudinal analysis of circulating B cells in
renal transplant recipients after treatment with tacro-
limus, MMF and steroids. Shown are the percentages of
transitional CD24++CD38++, mature CD24+CD38+, memory
CD24++CD382, naive IgD+CD272 and switched memory
IgD+CD272 B cells within the CD19+ B-cell population. Results
are shown as box plots displaying the median, 25th and 75th
percentiles as the box, and the 5th and 95th percentiles as whiskers.
Significant differences are indicated compared to pre-transplant
(t = 0) levels: *P,0.05, **P,0.01, ***P,0.001.
(EPS)
Figure S3 Longitudinal analysis of circulating B and T
cells in renal transplant recipients after treatment with
tacrolimus, MMF and steroids, and a single dose of
rituximab (RTX) during transplant surgery. (A) Shown are
the percentages of transitional CD24++CD38++, naive
IgD+CD272 and switched memory IgD+CD272 B cells within
the CD19+ B-cell population for RTX- (gray, n = 14) and triple IS-
treated (white, n = 12) patients before transplantation (t = 0) and
up to 24 months after transplantation (n = 10 and n = 9 at
t = 24 m, respectively). (B) The percentage of regulatory T
cells (TREGS; CD25
hiCD127lo), central memory (TCM;
CD27+CD45RO+), effector memory (TEM; CD27
2CD45RO+),
CXCR3+ and CCR6+ within the CD4+ T-cell population in
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RTX- (gray, n = 12) and triple IS-treated (white, n = 14) patients
before transplantation (t = 0) and up to 24 months after
transplantation (n = 10 and n = 9 at t = 24 m, respectively). (C)
Peripheral blood mononuclear cells (PBMCs) were stimulated for 4
hours in the presence of PMA, ionomycin and Brefeldin A. Shown
are the percentages IL-2, IL-4, IL-17, IFNc or TNFa-producing
cells within the CD4+ T-cell population in RTX- (gray, n = 12)
and triple IS-treated (white, n = 14) patients before transplantation
(t = 0) and up to 24 months after transplantation (n = 10 and n = 9
at t = 24 m, respectively). Results are shown as box plots displaying
the median, 25th and 75th percentiles as the box, and the 5th and
95th percentiles as whiskers. Significant differences are indicated
by asterisks: **P,0.01.
(EPS)
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